Across TCGA pan-cancer cohorts, EHMT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EHMT2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EHMT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EHMT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where EHMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.922	0.611	.006	25	view →
PDAC	OS	Tertile	III,IV	0.258	0.554	.012	11	view →
CCRCC	DFS	Tertile	All	0.925	0.642	.021	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: EHMT2 tumor-vs-normal RNA expression · all EHMT2 data types